A Review of Current and Emerging Therapeutic Options for Hemophagocytic Lymphohistiocytosis
Annals of Pharmacotherapy · 2023-07 · 57 (7) · 867-879
DOI: 10.1177/10600280221134719 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 09.11.2022. Verfasst von Jenna Summerlin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacy Practice, The University of Texas at Austin College of Pharmacy, Austin, TX, USA. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, COVID-19, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
Objective
To provide an overview of clinical sequelae and emerging treatment options for hemophagocytic lymphohistiocytosis (HLH). Data Sources: A literature search was conducted using the search terms “hemophagocytic lymphohistiocytosis,” “hemophagocytic syndrome,” “macrophage activation syndrome,” and “treatment” on Ovid and PubMed from January 1, 2017, through September 28, 2022. Study Selection and Data Extraction: Relevant clinical trials, meta-analyses, case reports, review articles, package inserts, and guidelines to identify current and emerging therapeutic options for the management of HLH. Data Synthesis: Genetic disorders and secondary causes may trigger HLH in both children and adults. Notable improvements in the diagnosis of HLH were seen with implementation of the HLH-2004 standard diagnostic criteria; however, timely and accurate identification of HLH remain significant barriers to optimal management. Multiagent immunochemotherapy are the backbone of aggressive therapy for acutely ill patients with HLH. Relevance to Patient Care and Clinical Practice: The global coronavirus 2019 (COVID-19) pandemic and emerging immune effector cell therapies have served to highlight the concerns with immune dysregulation and subsequent HLH precipitation. Without prompt identification and treatment, HLH can be fatal. Historically, the clinician’s armamentarium for managing HLH was sparse, with etoposide-based protocols serving as the standard of care. Relapsed or refractory disease portends a poor prognosis and requires additional treatment options. Second- or subsequent-line options now include hematopoietic stem cell transplantation, emapalumab, alemtuzumab, anakinra, ruxolitinib, and tocilizumab.
Conclusions
Improvements in diagnostic methods and novel immunosuppressive treatment strategies, including noncytotoxic immunochemotherapy, have transformed the therapeutic landscape. Unfortunately, many unanswered questions remain. Additional studies are required to optimize dosing, schedules, treatment sequences, and indications for novel treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacy Practice, The University of Texas at Austin College of Pharmacy, Austin, TX, USA.
- Internal Medicine, Department of Pharmacy, Methodist University Hospital, Memphis, TN, USA.
- The University of Texas Medical Branch, Galveston, TX, USA.
- Union University College of Pharmacy, Jackson, TN, USA.
ORCID-Profile: Jenna Summerlin, Drew A Wells, Mary Kate Anderson, Zachery Halford
Zitieren
APA
Summerlin, J., Wells, D. A., Anderson, M. K., & Halford, Z. (2023). A Review of Current and Emerging Therapeutic Options for Hemophagocytic Lymphohistiocytosis. Annals of Pharmacotherapy, 57(7), 867-879. https://doi.org/10.1177/10600280221134719
Vancouver
Summerlin J, Wells DA, Anderson MK, Halford Z. A Review of Current and Emerging Therapeutic Options for Hemophagocytic Lymphohistiocytosis. Annals of Pharmacotherapy. 2023;57(7):867-879. doi:10.1177/10600280221134719
BibTeX
@article{Summerlin2023,
author = {Summerlin, Jenna and Wells, Drew A and Anderson, Mary Kate and Halford, Zachery},
title = {A Review of Current and Emerging Therapeutic Options for Hemophagocytic Lymphohistiocytosis},
journal = {Annals of Pharmacotherapy},
year = {2023},
volume = {57},
number = {7},
pages = {867--879},
doi = {10.1177/10600280221134719}
}
EUVIMED